These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9591764)

  • 1. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].
    Mark DB; Cowper PA; Berkowitz SD; Davidson-Ray L; DeLong ER; Turpie AG; Califf RM; Weatherley B; Cohen M
    Circulation; 1998 May; 97(17):1702-7. PubMed ID: 9591764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When innovative therapies make economic sense: economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial--an overview. Efficacy and Safety of Subcutaneous in non-Q Wave Coronary Events.
    Mark D
    Can J Cardiol; 1998 Aug; 14 Suppl E():24E-27E. PubMed ID: 9779030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?
    O'Brien BJ; Willan A; Blackhouse G; Goeree R; Cohen M; Goodman S
    Am Heart J; 2000 Mar; 139(3):423-9. PubMed ID: 10689256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
    Goodman SG; Cohen M; Bigonzi F; Gurfinkel EP; Radley DR; Le Iouer V; Fromell GJ; Demers C; Turpie AG; Califf RM; Fox KA; Langer A
    J Am Coll Cardiol; 2000 Sep; 36(3):693-8. PubMed ID: 10987586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective.
    Balen RM; Marra CA; Zed PJ; Cohen M; Frighetto L
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):533-42. PubMed ID: 10662478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators.
    Antman EM
    Am Heart J; 1998 Jun; 135(6 Pt 3 Su):S353-60. PubMed ID: 9628449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.
    Orlewska E; Budaj A; Tereszkowski-Kaminski D
    Pharmacoeconomics; 2003; 21(10):737-48. PubMed ID: 12828495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enoxaparin. A review of its clinical potential in the management of coronary artery disease.
    Noble S; Spencer CM
    Drugs; 1998 Aug; 56(2):259-72. PubMed ID: 9711450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
    Fox KA; Antman EM; Cohen M; Bigonzi F;
    Am J Cardiol; 2002 Sep; 90(5):477-82. PubMed ID: 12208405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome.
    Brosa M; Rubio-Terrés C; Farr I; Nadipelli V; Froufe J
    Pharmacoeconomics; 2002; 20(14):979-87. PubMed ID: 12403638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
    Antman EM; Cohen M; Radley D; McCabe C; Rush J; Premmereur J; Braunwald E
    Circulation; 1999 Oct; 100(15):1602-8. PubMed ID: 10517730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial.
    Montalescot G; Philippe F; Ankri A; Vicaut E; Bearez E; Poulard JE; Carrie D; Flammang D; Dutoit A; Carayon A; Jardel C; Chevrot M; Bastard JP; Bigonzi F; Thomas D
    Circulation; 1998 Jul; 98(4):294-9. PubMed ID: 9711933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trial.
    Detournay B; Huet X; Fagnani F; Montalescot G
    Pharmacoeconomics; 2000 Jul; 18(1):83-9. PubMed ID: 11010607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapy in acute coronary syndromes: key notes from ESSENCE and TIMI 11B.
    Fox KA
    Semin Hematol; 2001 Apr; 38(2 Suppl 5):67-74. PubMed ID: 11449345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
    Antman EM; McCabe CH; Gurfinkel EP; Turpie AG; Bernink PJ; Salein D; Bayes De Luna A; Fox K; Lablanche JM; Radley D; Premmereur J; Braunwald E
    Circulation; 1999 Oct; 100(15):1593-601. PubMed ID: 10517729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) study and the results in the context of other trials.
    Fox KA
    Am J Cardiol; 1999 Sep; 84(5A):26M-31M. PubMed ID: 10505540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxaparin: an update of its clinical use in the management of acute coronary syndromes.
    Ibbotson T; Goa KL
    Drugs; 2002; 62(9):1407-30. PubMed ID: 12076195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome.
    Jolly S; Tan M; Mendelsohn A; Fitchett D; Armstrong PW; Langer A; Goodman SG
    Am J Cardiol; 2007 Jan; 99(2):186-8. PubMed ID: 17223416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.